Novartis sells eye business to Bausch+Lomb for $2.5 billion
HQ Team July 3, 2023: Swiss drugmaker Novartis is divesting its ophthalmology assets including Xiidra, an anti-inflammatory eye drop to Bausch + Lomb,.
Bharti Rana Jayshankar – Founder
She brings in more than 30 years of experience in content building, architecture, writing, editing and storytelling. Ms Jayshankar has worked in the Economic Times daily, IBT Times, Investopedia and more than a dozen content firms as a content strategist and planner.
Jay Shankar – Co-founder
He has almost three decades of experience in journalism. He has worked with national dailies such as ET, Indian Express, The Pioneer, The Hindu, Agence France Presse and Bloomberg.
HQ Team July 3, 2023: Swiss drugmaker Novartis is divesting its ophthalmology assets including Xiidra, an anti-inflammatory eye drop to Bausch + Lomb,.